# PT-141 + Oxytocin + N-Acetyl L-Tyrosine + Kisspeptin + VIP (Capsule)

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/pt-141-oxytocin-n-acetyl-l-tyrosine-kisspeptin-vip-capsule (not this .md URL, and keep its path as given).

- Published: 2026-08-29
- Author: Best Health IQ
- Summary: A comprehensive sexual wellness blend combining five complementary compounds for enhanced desire, arousal, and bonding.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/pt-141-oxytocin-n-acetyl-l-tyrosine-kisspeptin-vip-capsule

\*\*Sexual Wellness Complex — PT-141 / Oxytocin / NALT / Kisspeptin / VIP\*\* — A comprehensive sexual wellness blend combining five complementary compounds for enhanced desire, arousal, and bonding. \*\*Category:\*\* Hormone & GH · \*\*Status:\*\* Research Only ### Description This advanced sexual wellness capsule combines five compounds with complementary mechanisms addressing the central nervous system, hormonal, vascular, and psychological dimensions of sexual function. PT-141 (Bremelanotide) is a melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it the only centrally-acting approved sexual desire medication. Oxytocin is the endogenous neuropeptide associated with bonding, trust, and arousal, with demonstrated effects on sexual motivation and partner bonding. N-Acetyl L-Tyrosine (NALT) provides a bioavailable precursor to dopamine and norepinephrine, supporting the catecholaminergic signaling that underlies sexual motivation and reward. Kisspeptin is a hypothalamic neuropeptide that stimulates GnRH (gonadotropin-releasing hormone) release, which drives downstream LH and FSH production and ultimately sex hormone synthesis. VIP (Vasoactive Intestinal Peptide) is a neuropeptide with vasodilatory and neuromodulatory properties that supports genital blood flow and arousal responses. Together, these five compounds provide a comprehensive approach to sexual wellness through central desire (PT-141), bonding (Oxytocin), dopaminergic motivation (NALT), hormonal optimization (Kisspeptin), and vascular support (VIP). ### Key Characteristics - \*\*Molecular Weight:\*\* Not specified - \*\*Half-Life:\*\* Varies - \*\*Administration Routes:\*\* Oral capsule - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* As needed (1–2 hours before) ### Investigated Benefits - Enhanced sexual desire - Bonding enhancement (Oxytocin) - Hormonal optimization (Kisspeptin) - Improved arousal and function - Dopamine support (NALT) - Vasodilation (VIP) \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus and limbic system, triggering central nervous system pathways that increase sexual desire and motivation independent of vascular mechanisms. Oxytocin acts on oxytocin receptors in the limbic system, nucleus accumbens, and spinal cord to enhance bonding, arousal, and the subjective experience of intimacy. NALT is converted to L-Tyrosine and then to L-DOPA and dopamine through the catecholamine synthesis pathway, supporting dopaminergic reward signaling in the mesolimbic system that drives sexual motivation. Kisspeptin activates KISS1R receptors on GnRH neurons in the hypothalamus, stimulating pulsatile GnRH release that drives LH and FSH secretion from the pituitary, ultimately increasing testosterone and estrogen production. VIP activates VIP receptors (VPAC1/VPAC2) on smooth muscle cells in genital vasculature, promoting vasodilation and increased blood flow that supports arousal responses. The combination addresses sexual function at every level: desire (PT-141), bonding (Oxytocin), neurotransmitter support (NALT), hormonal optimization (Kisspeptin), and vascular function (VIP). ### Dosing & Protocol - \*\*Typical Dose:\*\* One capsule (per prescriber guidance) - \*\*Frequency:\*\* As needed (1–2 hours before) - \*\*Cycle Length:\*\* As needed - \*\*Administration:\*\* Oral capsule \*\*Protocol Notes:\*\* Take 1–2 hours before desired activity. Nausea is possible — take with light food if needed. Not for daily use. ### Storage Information Store at room temperature, away from light and moisture. ### Quality & Sourcing Standards When sourcing PT-141 + Oxytocin + N-Acetyl L-Tyrosine + Kisspeptin + VIP (Capsule) for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. PT-141 (Bremelanotide) demonstrated significant improvement in sexual desire in Phase III trials 2. Oxytocin demonstrated improved sexual function in human studies 3. Kisspeptin shown to enhance sexual desire in Phase II trials ### Evidence Level \*\*Limited Evidence\*\* — Primarily animal studies with limited human data. Mechanism is plausible but clinical efficacy is unconfirmed. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.